Hippo Signaling in Cancer (2nd Edition)
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Tumor Microenvironment".
Deadline for manuscript submissions: 31 December 2025 | Viewed by 80
Special Issue Editors
2. Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE 68198, USA
Interests: Hippo; pancreatic cancer; telomeres/telomerase; Rac1; GTPase; K-ras signaling
Special Issues, Collections and Topics in MDPI journals
Interests: Hippo; AKT1; phosphorylation; radiation; DSB
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
This Special Issue in Cancers aims to present the current achievements of scientific investigations focusing on Hippo signaling, with emphasis on oncogenesis, cancer progression, metastasis, cancer therapy resistance, and the development of targeted anticancer agents based on Hippo signaling. The topic is of particular importance because the dysregulation of Hippo signaling occurs in many types of human cancer and contributes to cancer development, progression, metastasis, and therapeutic resistance. Recent advances in methods and technologies of cell biology, molecular biology, immunology, and biochemistry have enabled fast growth in this area. This Special Issue aims to present the most important recent achievements in this unique field of cancer research; original research articles and reviews are welcome.
Prof. Dr. Michel Ouellette
Dr. Ying Yan
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Hippo signaling
- Salvador–Warts–Hippo (SWH) pathway
- YAP/TAZ
- cancer development
- progression
- metastasis
- therapeutic resistance
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
